Fjarde AP Fonden Fourth Swedish National Pension Fund Lowers Position in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its stake in Zimmer Biomet Holdings by 29.3%, owning 24,347 shares worth approximately $2.756 million after selling 10,100 shares.
• Several other institutional investors increased their positions in Zimmer Biomet, with JPMorgan Chase & Co. leading with a 251.3% increase during the first quarter, now holding over 2 million shares.
• Zimmer Biomet recently reported $2.08 billion in quarterly revenue, surpassing analyst expectations, and announced a quarterly dividend of $0.24 per share, yielding 0.9% annually.

Fjarde AP Fonden Fourth Swedish National Pension Fund lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 29.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,347 shares of the medical equipment provider's stock after selling 10,100 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Zimmer Biomet were worth $2,756,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Garde Capital Inc. bought a new stake in shares of Zimmer Biomet in the 1st quarter valued at about $29,000. Menard Financial Group LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $30,000. Washington Trust Advisors Inc. bought a new stake in shares of Zimmer Biomet in the 1st quarter valued at about $30,000. Columbia River Financial Group LLC bought a new stake in shares of Zimmer Biomet in the 1st quarter valued at about $30,000. Finally, Accent Capital Management LLC bought a new stake in shares of Zimmer Biomet in the 1st quarter valued at about $35,000. Institutional investors own 88.89% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ZBH shares. JPMorgan Chase & Co. reduced their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Evercore ISI dropped their price objective on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Raymond James Financial boosted their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Royal Bank Of Canada boosted their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Finally, The Goldman Sachs Group dropped their price objective on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Nine analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and an average price target of $111.44.

Insider Activity

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider owned 20,424 shares in the company, valued at $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.70% of the stock is currently owned by corporate insiders.

Zimmer Biomet Stock Performance

NYSE ZBH traded up $1.3780 on Wednesday, hitting $105.6880. 1,844,246 shares of the stock traded hands, compared to its average volume of 2,066,566. The business's fifty day moving average is $94.74 and its two-hundred day moving average is $99.30. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $116.71. The firm has a market capitalization of $20.94 billion, a price-to-earnings ratio of 25.71, a PEG ratio of 2.02 and a beta of 0.68. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same period in the prior year, the company earned $2.01 earnings per share. Zimmer Biomet's revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, June 26th. Zimmer Biomet's dividend payout ratio is 23.36%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.